FreeStyle LibreLink app users spend more time in ‘target glucose range’ compared to traditional reader users, new data shows

By Editor
30th September 2021
Glucose monitoring, Research

People living with diabetes who use the FreeSytyle Libre digital app spend five percent more time in their target glucose range – otherwise known as Time in Range – compared to those who use a traditional reader, new research has revealed. 

The free-of-charge FreeStyle LibreLink app enables FreeStyle Libre and FreeStyle Libre 2 system users to receive glucose readings from a small sensor worn on the back of the upper arm, directly to compatible smartphones.

Time in Range (TIR) captures the percentage of time in a day a person with diabetes spends in the target glucose range. The recommended range for most people living with diabetes is 3.9 – 10.0 mmol/L. Every extra hour spent in range has a positive impact on glucose control and a five percent difference represents a clinically significant hour per day approximately.

These results may be the outcome of data sharing features of the FreeStyle LibreLink app, which allows healthcare professionals, caregivers, and people living with diabetes to easily view Time in Target reports and receive immediate glucose feedback to make more informed treatment decisions.

Mahmood Kazemi, Global Medical and Scientific Affairs and Chief Medical Officer for Abbott said: “Time in Range is a critical metric for diabetes management because it gives that immediate visibility into glucose levels.

“FreeStyle Libre sensor-based technology and digital health solutions simplify the experience of staying in target range by providing real-time, actionable data delivered straight to smartphones and removing the need for a separate reader.”

He said: “This technology helps people living with diabetes make lifestyle choices that are personalised to their own target data and provides an achievable goal that leads to better health outcomes.”

In addition, the real-world data shows that FreeStyle LibreLink app users also experienced lower glucose variability, lower average glucose, and less time in hyperglycemia than reader users.

These results also bolster the importance of sharing data with healthcare professionals through telehealth for remote glucose monitoring.

During the COVID-19 pandemic, international studies found that FreeStyle Libre users with type 1 diabetes increased their TIR by up to four percent over the lockdown period, with associated improvements in glycaemic variability and estimated HbA1c.

“At the onset of COVID-19, the healthcare community quickly adapted to a virtual world and thanks to our digital connections with glucose sensor technology, we were able to remotely monitor and guide our patients,” said Thomas Danne, director of the Department of General Paediatrics and Endocrinology/Diabetology at the Auf der Bult Hospital, Hanover, Germany.

He added: “This adoption of telehealth creates a new standard for healthcare. As we emerge from this pandemic, we can continue to actively manage diabetes remotely. Together with our patients, we can make informed decisions to improve Time in Range.”

To continue to help improve the daily lives of people with diabetes, Abbott has joined forces with Novo Nordisk and the diatribe Foundation to increase awareness around the importance of TIR and advance standard of care.

The global campaign, ‘It’s Time for Time in Range’, provides TIR education, clinical guidance, expert insights and resources to healthcare providers via 

Providing breakthrough technology that is accessible and affordable, the FreeStyle Libre portfolio is the world-leading glucose sensor-based technology that has changed the lives of nearly 3.5 million people across more than 50 countries.

Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 38 countries, including Canada, France, Germany, Japan, the United Kingdom, and the U.S.

The entire research study is now available in the Journal of Diabetes Science and Technology.

Photo by freestocks on Unsplash

Comments (0)

Register an account or login to comment